See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat several health conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. However, there are certain health conditions that may contraindicate the use of Cosentyx.

According to the Cosentyx prescribing information, the medication should not be used in individuals with a history of hypersensitivity to secukinumab or any of the excipients in Cosentyx [2]. Additionally, Cosentyx should not be used in individuals with active tuberculosis (TB) or active serious infections such as sepsis, opportunistic infections, or viral hepatitis [2].

Furthermore, Cosentyx may increase the risk of infection and should be used with caution in individuals with chronic or recurring infections, or who have been exposed to tuberculosis [2]. It is also recommended to monitor patients for signs and symptoms of infection during and after treatment with Cosentyx [2].

It is important to note that this information is not exhaustive and other health conditions may also contraindicate the use of Cosentyx. Therefore, it is essential to consult with a healthcare provider for a comprehensive evaluation of any potential contraindications before starting treatment with Cosentyx.

In summary, Cosentyx is contraindicated in individuals with a history of hypersensitivity to secukinumab or any of the excipients in Cosentyx, active tuberculosis or active serious infections, and should be used with caution in individuals with chronic or recurring infections or who have been exposed to tuberculosis.

Sources:
[1] Drugs.com. Cosentyx. <https://www.drugs.com/cosentyx.html>.
[2] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) Prescribing Information. January 2023. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>.
[3] DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.